Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04747197 · ClinicalTrials.gov registry record · Phase 1
First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)
A Phase 1 study, sponsored by EyePoint Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT04747197 is a Phase 1 study that has completed, run by EyePoint Pharmaceuticals. The registered enrollment target is 17 participants.
The verdict
NCT04747197, a Phase 1 study, has completed, sponsored by EyePoint Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Phase 1 open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of a single dose injections of EYP-1901 at three dose levels: 440 µg, 2060 µg and 3090 µg in subjects with Wet Age Related Macular Degeneration (wAMD)
Interventions
- DRUG EYP-1901
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-01-20 |
| Est. Completion | 2022-05-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04747197
The ClinicalTrials.gov registry entry for NCT04747197 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EyePoint Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EYP-1901 is the first listed.
NCT04747197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04747197 about?
NCT04747197 is a clinical study titled "First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)". Phase 1 open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of a single dose injections of EYP-1901 at three dose levels: 440 µg, 2060 µg and 3090 µg in subjects with Wet Age Related Macular Degeneration (wAMD)
What is the current status of trial NCT04747197?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2021-01-20. Estimated completion is 2022-05-11.
What interventions are being tested in trial NCT04747197?
The interventions under investigation include: EYP-1901 (DRUG).
Who is sponsoring clinical trial NCT04747197?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.